Mendus AB: Kommuniké från extra bolagsstämma i Mendus AB (publ) den 18 november 2022
Vid extra bolagsstämma i Mendus AB (publ), org. nr 556629-1786, (”Bolaget”) den 18 november 2022 fattades bland annat följande beslut. För mer detaljerad information om innehållet i beslutet hänvisas till kallelsen till den extra bolagsstämman samt fullständigt förslag till beslut, som tidigare har publicerats och finns tillgängliga på Bolagets hemsida, www.mendus.com.
Bemyndigande för styrelsen att fatta beslut om nyemission samt emission av teckningsoptioner och/eller konvertibler
Den extra bolagsstämman beslutade om bemyndigande för styrelsen att under tiden intill nästa årsstämma, vid ett eller flera tillfällen och med eller utan avvikelse från aktieägarnas företrädesrätt, fatta beslut om nyemission av aktier samt emission av teckningsoptioner eller konvertibler mot kontant betalning och/eller med bestämmelse om apport eller kvittning eller eljest med villkor.
Antalet aktier, eller teckningsoptioner eller konvertibler som berättigar till teckning av aktier, som ska kunna emitteras ska uppgå till högst 20 procent av antalet registrerade aktier i Bolaget vid tidpunkten för styrelsens första beslut enligt bemyndigandet. Vid efterföljande beslut enligt bemyndigandet ska gränsen om 20 procent baseras på (i) antalet aktier som nyemitterats med stöd av bemyndigandet, samt, avseende teckningsoptioner och konvertibler som emitterats med stöd av bemyndigandet, (ii) det antalet aktier som emitterats genom teckning av utgivna teckningsoptioner, och (iii) det antalet aktier som emitterats genom konvertering av utgivna konvertibler, under förutsättning att teckning/konvertering av sådana teckningsoptioner/konvertibler har skett.
Bemyndigandet ersätter det bemyndigande som årsstämman den 10 maj 2022 fattade beslut om.
FÖR MER INFORMATION VÄNLIGEN KONTAKTA:
Christine Lind
Styrelseordförande
E-post: info@mendus.com
OM MENDUS AB (PUBL)
Mendus förändrar behandlingen av cancer genom att fokusera på tumöråterfall och förbättra överlevnaden för cancerpatienter, samtidigt som livskvaliteten bevaras. Vi utnyttjar vår oöverträffade expertis inom allogen dendritcellsbiologi för att utveckla en avancerad klinisk pipeline av nya, lagringsbara, cellbaserade immunterapier som kombinerar klinisk effekt med en god säkerhetsprofil. Mendus är baserat i Sverige och Nederländerna och handlas på Nasdaq Stockholm under tickern IMMU.ST. https://www.mendus.com
Bilaga
För att se det här innehållet från www.globenewswire.com måste du ge ditt medgivande sidans topp.För att se det här innehållet från ml-eu.globenewswire.com måste du ge ditt medgivande sidans topp.
Om
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Följ GlobeNewswire by notified
Abonnera på våra pressmeddelanden. Endast mejladress behövs och den används bara här. Du kan avanmäla dig när som helst.
Senaste pressmeddelandena från GlobeNewswire by notified
Basilea announces that FDA approves expanded use of antifungal Cresemba® (isavuconazole) in the United States in children with invasive aspergillosis and invasive mucormycosis11.12.2023 07:15:00 CET | Press release
Allschwil, Switzerland, December 11, 2023 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that its license partner Astellas Pharma US, Inc. (“Astellas”) received the approval of Cresemba® (isavuconazole) for the treatment of invasive aspergillosis (IA) and invasive mucormycosis (IM) in pediatric patients by the US Food and Drug Administration (FDA). Cresemba for injection is approved for adults and now for pediatric patients 1 year of age and older. Cresemba capsules are approved for adults and now for pediatric patients 6 years of age and older, who weigh 16 kilograms and greater. Dr. Marc Engelhardt, Chief Medical Officer of Basilea, said: “We congratulate Astellas on the approval of Cresemba for the use in children who suffer from invasive aspergillosis or mucormycosis. These severe mold infections primarily affect children suffering
Novartis investigational iptacopan Phase III study demonstrates clinically meaningful and statistically significant proteinuria reduction in patients with C3 glomerulopathy (C3G)11.12.2023 07:15:00 CET | Press release
Ad hoc announcement pursuant to Art. 53 LR Phase III APPEAR-C3G study met its primary endpoint, demonstrating superiority of iptacopan vs. placebo in proteinuria reduction at six-month analysis1; the safety profile of iptacopan was consistent with previously reported data1-3 C3 glomerulopathy (C3G) is an ultra-rare complement-mediated kidney disease, with approximately 50% of patients progressing to kidney failure within 10 years of diagnosis4-7; currently no treatments address the underlying cause of C3G7-9 Novartis plans to review results with global health authorities to enable potential submissions in 2024; data will be submitted for presentation at an upcoming medical meeting Iptacopan demonstrated positive Phase III results in IgA nephropathy (IgAN) at the interim analysis and a late-stage development program is ongoing across four investigational indications10-14 Basel, December 11, 2023 — Novartis today announced positive topline results from the six-month, double-blind period
Nokia and BT Group sign agreement to drive new 5G monetization opportunities through telco APIs11.12.2023 07:00:00 CET | Press release
Press Release Nokia and BT Group sign agreement to drive new 5G monetization opportunities through telco APIs Memorandum of understanding covers the utilization of Nokia’s Network as Code platform and developer portal with BT Group’s cloud-native network 11 December 2023 Espoo, Finland – Nokia and BT Group today announced an agreement to develop new 5G network monetization opportunities through Nokia’s Network as Code platform with developer portal (platform) and BT Group’s cloud-native network. BT Group, which operates EE – the UK’s best mobile network1 – is, like other communications service providers, looking to Nokia’s growing ecosystem of developer partners to gain access to simplified network capabilities in the form of software code that can be built into applications for enterprise, industrial, and consumer use cases. The Nokia platform helps operators monetize their 5G network assets beyond pure connectivity. It provides application developers with tools such as Software Devel
New data for Roche’s Columvi and Lunsumio presented at ASH 2023 support continued benefit for people with lymphoma11.12.2023 07:00:00 CET | Press release
Longer-term data from pivotal studies of fixed-duration Columvi and Lunsumio continue to show durable responses in people with heavily pre-treated lymphomas1,2New data reinforce the potential of combination regimens in earlier treatment settings and add to the robust body of evidence supporting ongoing Phase III studies3,4,5,6 Basel, 11 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that new data from its CD20xCD3 T-cell engaging bispecific antibody programme, including eight oral presentations, were presented at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition, 9-12 December 2023. Based on 32-month and 3-year follow-ups of two pivotal studies for fixed-duration treatments of Columvi® (glofitamab) and Lunsumio® (mosunetuzumab), respectively, data show that remissions were maintained in the majority of patients with heavily pre-treated lymphomas.1,2 Additionally, new early-phase data of novel Columvi or Lunsumio combination regimens support o
Press Release: Sarclisa® (isatuximab) plus KRd significantly improved rate of minimal residual disease negativity in transplant-eligible patients with newly diagnosed multiple myeloma versus KRd alone11.12.2023 01:30:59 CET | Press release
Sarclisa® (isatuximab) plus KRd significantly improved rate of minimal residual disease negativity in transplant-eligible patients with newly diagnosed multiple myeloma versus KRd alone Phase 3 data showed Sarclisa added to carfilzomib, lenalidomide and dexamethasone (KRd) in patients with newly diagnosed, transplant-eligible multiple myeloma resulted in 77% of patients achieving minimal residual disease (MRD) negativity after consolidation therapy, detected with a sensitivity of 10-5MRD negativity rate measured at a sensitivity of 10-6 was 67% for Sarclisa combination therapyResults shared during oral presentation at ASH 2023 plenary scientific session PARIS, December 10, 2023. The Phase 3 trial investigating Sarclisa® (isatuximab) in combination with carfilzomib, lenalidomide and dexamethasone (KRd) showed a statistically significant improvement in the rate of minimal residual disease (MRD) negativity, compared with KRd alone, after autologous stem cell transplant (ASCT) consolidatio